Unicentric Form of Castleman Disease - Surgery Therapy Benefit
Sponsor
Charles University, Czech Republic (Other)
Overall Status
Completed
CT.gov ID
NCT05440305
Collaborator
(none)
20
135.9
Study Details
Study Description
Brief Summary
Observation study on patients with unicentric form of Castleman disease, evaluation of surgical treatment benefit. Observation of surgical treatment strategy.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
20 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Castleman Disease - Diagnosis and Surgery
Actual Study Start Date
:
Jan 1, 2011
Actual Primary Completion Date
:
Dec 31, 2021
Actual Study Completion Date
:
Apr 30, 2022
Outcome Measures
Primary Outcome Measures
- 5 year survival [each 6 months checkup, up to 150 weeks, from date of randomization until the date of first documented progression]
surgery treatment success
- recurence rate [each 6 months checkup, up to 150 weeks, from date of randomization until the date of first documented progression]
surgery treatment success
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
patient with unicentric form of Castleman disease
-
underwent surgery resection
Exclusion Criteria:
- multilocalised Castleman disease
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Charles University, Czech Republic
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Jiri Molacek,
Principal investigator,
Charles University, Czech Republic
ClinicalTrials.gov Identifier:
NCT05440305
Other Study ID Numbers:
- 750923
First Posted:
Jun 30, 2022
Last Update Posted:
Jun 30, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jiri Molacek,
Principal investigator,
Charles University, Czech Republic
Additional relevant MeSH terms: